⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OSTX News
OS Therapies Incorporated
OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Enters into Warrant Inducement Agreements Ready to Announce with Confidence?
newsfilecorp.com
OSTX
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of OS Therapies Incorporated (NYSE American: OSTX)
prnewswire.com
OSTX
OS Therapies Provides First Half 2026 Corporate Outlook Ready to Announce with Confidence?
newsfilecorp.com
OSTX
OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
newsfilecorp.com
OSTX
OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility
newsfilecorp.com
OSTX
OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
newsfilecorp.com
OSTX